Abstract:Objective: To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Methods: Patients confirmed pathologically with cancer and complicated with moderate to severe pain, were divided into control and experimental groups. Oxycodone prolonged-release tablets, with or without fluvoxamine, were administrated to all study patients until pain relief. Degree of pain relief, dose of oxycodone prolonged-release tablets, side effects and quality of life were compared before and after treatment. Results: In total, 120 patients were recruited. No statistically significant difference was detected regarding age, gender, types of cancer, KPS between two groups of patients (P> 0.05). Baseline pain score of patients with moderate pain in treatment and control group was 4.9±0.8 and 5.1±0.8, respectively; and decreased to 1.8±1.1 and 1.2±1.1 after treatment, respectively. Pain intensity was significantly reduced in the treatment group (P =0.028). Average daily consumption of oxycodone prolonged- release tablets was (54.0±19.6) mg and (44.7± 18.7) mg respectively, which is lower in treatment grpup than in control group, but the difference was not statistically significant (P=0.065). Baseline pain score of patients with severe pain in treatment and control groups were 8.3±1.1 and 8.3±1.1, respectively; and pain intensity after treatment decreased to 2.9±1.0 and 2.3±1.0. Pain intensity was significantly reduced in the treatment group, with statistical significance (P =0.026). Average daily consumption of oxycodone prolonged-release tablets was (132.0±42.2) mg and (110.7±33.9) mg, respectively, which is lower in treatment group than in control group, and the difference was statistically significant (P=0.035). In terms of quality of life, patients in treatment group had better performance status, daily activity, mood, and sleep than that in control group (P < 0.05). Patients in two groups had similar side effects, eg., constipation, nausea/vomiting, lethargy, dizziness, itchy skin, dysuria, and ataxia. Lower incidence of nausea/vomiting, lethargy, was obtained from patients in treatment than in control group, while significant low constipation was observed in treatment than in control group (35.0% vs 49.2%, P=0.026). Conclusion: Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life.

The therapeutic efficacy of oxycodone hydrochloride prolonged-release tablets combined with bioelectric stimulation in treatment Of neuropathological cancer pain

Evaluation on postoperative analgesia efficacy of oxycodone combined with dexmedetomidine in patients underwent laparoscopic radical surgery of colon cancer

Clinical observation of oxycodone hydrochloride controlled-release tablet for moderate to severe cancer pain

Clinical study of Controlled-Release Oxycodone on moderate and severe chronic cancer pain

Clinical Observation of Oxycodone Hydrochloride Controlled-release Tablets in the Treatment of Moderate to Severe Cancer Pain

The observation of curative effect of oxycodone hydrochloride controlled-release tablets in management of moderate and severe cancer pain

Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain

Efficacy and Safety of High-Dose Controlled-Released Oxycodone for Cancer Pain

Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study.

PROSPECTIVE STUDY OF CALCIUM CHANNEL BLOCKER COMBINED WITH OPIOIDS ON NEUROPATHIC CANCER PAIN

Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain

The Efficacy of Gabapentin Combined with Opioids for Neuropathic Cancer Pain: a Meta-Analysis

Health Informatics of Oxycodone Hydrochloride Sustained-Release Tablets for Cancer Pain Treatment with Support of Computed Tomography Diagnosis

Observation of the Curative Effects of Oxycodone Hydrochloride Controlled-release Tablets for Moderate to Severe Cancer Pain

Efficacy and Safety of Sustained-Release Oxycodone Compared with Immediate-Release Morphine for Pain Titration in Cancer Patients: A Multicenter, Open-Label, Randomized Controlled Trial (SOCIAL).

Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: a Prospective Multicenter Cohort Study.

The Efficacy of Telemedicine for Pain Management in Patients with Cancer: a Systematic Review and Meta-Analysis

Clinical observation of individualizational controlled-release oxycodone in the treatment of outpatients with moderate-to-severe cancer pain

The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study

The efficacy of pain treatment and quality of life in lung cancer survivors under the model of medical institution-community referral

Clinical Observation of Cyclooxygenase -2 Inhibitor Celecoxib Combined with Oxycontin in Treatment of Moderate and Severe Cancer Pain